What does a FibroScan showing a Controlled Attenuation Parameter of 299 dB/m and a liver stiffness measurement of 10.1 kPa indicate, and what management is recommended?

FibroScan Interpretation: Moderate Steatosis with Significant Fibrosis

Your FibroScan results indicate moderate hepatic steatosis (CAP 299 dB/m) and significant liver fibrosis at the F2-F3 threshold (LSM 10.1 kPa), requiring immediate evaluation for metabolic dysfunction-associated steatotic liver disease (MASLD) and initiation of risk factor modification.

Understanding Your Results

Steatosis Assessment (CAP 299 dB/m)

Your CAP value of 299 dB/m falls just below the threshold for moderate-to-severe steatosis. Based on validated cutoffs 1:

• S≥S1 (any steatosis): Cutoff 302 dB/m - you are just below this
• S≥S2 (moderate steatosis): Cutoff 331 dB/m - you do not meet this threshold
• This suggests mild-to-moderate steatosis (approximately 5-33% hepatocyte involvement)

Important caveat: CAP measurements with an interquartile range (IQR) ≥40 dB/m have reduced accuracy 2. Ensure your measurement had adequate quality control (IQR <40 dB/m) for reliable interpretation.

Fibrosis Assessment (LSM 10.1 kPa)

Your liver stiffness of 10.1 kPa is concerning and indicates significant fibrosis. According to validated thresholds 3, 1:

• F≥F2 (significant fibrosis): Cutoff 8.2-9.9 kPa - you exceed this
• F≥F3 (advanced fibrosis): Cutoff 9.7 kPa - you are at or just above this threshold
• F4 (cirrhosis): Cutoff 13.6 kPa - you have not reached this

The EASL guidelines 4 emphasize that LSM can overestimate fibrosis in the presence of inflammation, cholestasis, recent food intake (<3 hours fasting), or venous congestion. However, your value is sufficiently elevated to warrant serious concern.

Critical Clinical Context

Your CAP value may be causing LSM overestimation. Research demonstrates that higher CAP values (particularly >299 dB/m, which is your exact value) are associated with false-positive LSM results for advanced fibrosis 5. In patients with F0-F2 fibrosis but CAP values in the middle tertile (299-338 dB/m), the false-positive rate for F3-F4 fibrosis increases to 16.6% compared to 7.2% in those with lower CAP values.

Recommended Management Algorithm

Step 1: Calculate Non-Invasive Fibrosis Scores

Immediately calculate FIB-4 and NAFLD Fibrosis Score (NFS) using readily available laboratory values 3:

• FIB-4 = [Age × AST] / [Platelets × √ALT]

  • <1.45: Low probability of advanced fibrosis
  • 1.45-3.25: Indeterminate

  • 3.25: High probability of advanced fibrosis

• NFS: Use online calculator with age, BMI, diabetes status, platelet count, albumin, AST/ALT ratio

  • <-1.455: Excludes advanced fibrosis (90% sensitivity)

  • 0.676: Indicates advanced fibrosis (67% sensitivity, 97% specificity)

Step 2: Risk Stratification Based on Combined Results

If FIB-4 <1.45 AND NFS <-1.455:

• Your LSM is likely overestimated by steatosis
• Repeat FibroScan in 6-12 months with strict 3-hour fasting 4
• Aggressive metabolic risk factor modification
• No immediate liver biopsy needed

If FIB-4 1.45-3.25 OR NFS indeterminate:

• Strongly consider liver biopsy 3 - you are in the zone where biopsy provides the most clinical value
• Alternative: MR elastography if available (more accurate than FibroScan in this context)
• Hepatology referral recommended

If FIB-4 >3.25 OR NFS >0.676:

• Liver biopsy strongly recommended to confirm F3-F4 fibrosis and assess for NASH 3
• Immediate hepatology referral
• Screen for varices if F3-F4 confirmed
• Consider clinical trial enrollment

Step 3: Address Metabolic Risk Factors

Regardless of final fibrosis stage, your results mandate aggressive intervention:

• Screen for metabolic syndrome components: Elevated uric acid and metabolic syndrome are strongly associated with severe steatosis (CAP ≥300 dB/m) 6
• Weight loss target: 7-10% body weight reduction (proven to improve both steatosis and fibrosis)
• Diabetes management: Optimize glycemic control if diabetic
• Cardiovascular risk assessment: MASLD patients have increased cardiovascular mortality

Step 4: Ensure Proper FibroScan Technique

Before making definitive decisions, verify your FibroScan was performed correctly 4:

• Minimum 3-hour fasting (not the older 2-hour recommendation)
• Adequate probe selection (M vs XL based on BMI)
• Valid measurement criteria met (IQR/median <0.30 for LSM, IQR <40 dB/m for CAP)
• No recent vigorous exercise
• No acute hepatic inflammation or cholestasis

Key Pitfalls to Avoid

1. Do not dismiss the LSM value solely because CAP is borderline - while CAP may cause overestimation, 10.1 kPa is high enough to warrant full evaluation 5

2. Do not rely on FibroScan alone - the AASLD guidance 3 explicitly states that NFS and FIB-4 should be used in conjunction with elastography for optimal risk stratification

3. Do not delay evaluation - patients with LSM values in your range who have true F3 fibrosis are at risk for progression to cirrhosis and hepatocellular carcinoma

4. Do not assume normal liver enzymes exclude significant disease - MASLD can have advanced fibrosis with normal ALT/AST

Bottom Line

Your FibroScan suggests you are at the critical F2-F3 fibrosis boundary where intervention can still reverse disease. The combination of LSM 10.1 kPa with CAP 299 dB/m requires correlation with FIB-4/NFS scores and likely liver biopsy to definitively stage your disease and guide management 3. This is not a "wait and see" result - it demands action now while fibrosis may still be reversible.